EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The Molecular Impact of Glucosylceramidase Beta 1 (Gba1) in Parkinson’s Disease: a New Genetic State of the Art

Júlio César Claudino Dos Santos, Gabriela Braga Cabrera Mano, André Rodrigues da Cunha Barreto-Vianna, Tulia Fernanda Meira Garcia, Aline Vieira de Vasconcelos, Caio Sérgio Gomes Sá, Sarah Lopes de Souza Santana, Ana Gabriela Ponte Farias, Beatriz Seimaru, Micael Porto Portela Lima, João Vitor Caetano Goes, Camilla Teixeira Pinheiro Gusmão und 1 weitere

Molecular Neurobiology · 2024-09 · 61 (9) · 6754-6770

DOI: 10.1007/s12035-024-04008-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Neurobiology, online erschienen am 13.02.2024. Verfasst von Júlio César Claudino Dos Santos und 12 weiteren Autor:innen. Beteiligte Einrichtung: Christus University Center, UNICHRISTUS, Fortaleza, Ceara, Brazil. julio.santos@alu.ufc.br. Hauptthemen laut MEDLINE: Glucosylceramidase, Parkinson Disease, Mutation. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Fundação Cearense de Apoio ao Desenvolvimento Científico e Tecnológico, Conselho Nacional de Desenvolvimento Científico e Tecnológico.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson's disease (PD) is a neurodegenerative disorder affecting 2-3% of those aged over 65, characterized by motor symptoms like slow movement, tremors, and muscle rigidity, along with non-motor symptoms such as anxiety and dementia. Lewy bodies, clumps of misfolded proteins, contribute to neuron loss in PD. Mutations in the GBA1 gene are considered the primary genetic risk factor of PD. GBA1 mutations result in decreased activity of the lysosomal enzyme glucocerebrosidase (GCase) resulting in α-synuclein accumulation. We know that α-synuclein aggregation, lysosomal dysfunction, and endoplasmic reticulum disturbance are recognized factors to PD susceptibility; however, the molecular mechanisms connecting GBA1 gene mutations to increased PD risk remain partly unknown. Thus, in this narrative review conducted according to a systematic review method, we aimed to present the main contributions arising from the molecular impact of the GBA1 gene to the pathogenesis of PD providing new insights into potential impacts for advances in the clinical care of people with PD, a neurological disorder that has contributed to the substantial increase in the global burden of disease accentuated by the aging population. In summary, this narrative review highlights the multifaceted impact of GBA1 mutations in PD, exploring their role in clinical manifestations, genetic predispositions, and molecular mechanisms. The review emphasizes the importance of GBA1 mutations in both motor and non-motor symptoms of PD, suggesting broader therapeutic and management strategies. It also discusses the potential of CRISPR/Cas9 technology in advancing PD treatment and the need for future research to integrate these diverse aspects for improved diagnostics and therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosylceramidaseParkinson DiseaseMutationHumansAnimalsGenetic Predisposition to Diseasealpha-Synuclein

Stichwörter der Autor:innen

GBA1Molecular mechanismsMutationsParkinson’s disease

Substanzen

Glucosylceramidasealpha-SynucleinGBA protein, human

Autor:innen und Institutionen

  • Christus University Center, UNICHRISTUS, Fortaleza, Ceara, Brazil. julio.santos@alu.ufc.br.
  • Center for Research and Drug Development (NPDM), Federal University of Ceara, Fortaleza, Ceara, Brazil. julio.santos@alu.ufc.br.
  • Postgraduate Program in Morphofunctional Sciences, Federal University of Ceará, Fortaleza, Ceara, Brazil. julio.santos@alu.ufc.br.
  • Faculty of Medical Sciences of, Santa Casa de São Paulo, São Paulo, SP, Brazil.
  • Federal University of Paraná, Pelotas, Parana, Brazil.
  • Multicampi School of Medical Sciences, Federal University of Rio Grande Do Norte, Caico, Rio Grande Do Norte, Brazil.

Förderung

  • Fundação Cearense de Apoio ao Desenvolvimento Científico e Tecnológico
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico

Zitieren

APA

Dos Santos, J. C. C., Mano, G. B. C., da Cunha Barreto-Vianna, A. R., Garcia, T. F. M., de Vasconcelos, A. V., Sá, C. S. G., de Souza Santana, S. L., Farias, A. G. P., Seimaru, B., Lima, M. P. P., Goes, J. V. C., Gusmão, C. T. P., & Junior, H. L. R. (2024). The Molecular Impact of Glucosylceramidase Beta 1 (Gba1) in Parkinson’s Disease: a New Genetic State of the Art. Molecular Neurobiology, 61(9), 6754-6770. https://doi.org/10.1007/s12035-024-04008-8

Vancouver

Dos Santos JCC, Mano GBC, da Cunha Barreto-Vianna AR, Garcia TFM, de Vasconcelos AV, Sá CSG, et al. The Molecular Impact of Glucosylceramidase Beta 1 (Gba1) in Parkinson’s Disease: a New Genetic State of the Art. Molecular Neurobiology. 2024;61(9):6754-6770. doi:10.1007/s12035-024-04008-8

BibTeX
@article{DosSantos2024,
  author = {Dos Santos, Júlio César Claudino and Mano, Gabriela Braga Cabrera and da Cunha Barreto-Vianna, André Rodrigues and Garcia, Tulia Fernanda Meira and de Vasconcelos, Aline Vieira and Sá, Caio Sérgio Gomes and de Souza Santana, Sarah Lopes and Farias, Ana Gabriela Ponte and Seimaru, Beatriz and Lima, Micael Porto Portela and Goes, João Vitor Caetano and Gusmão, Camilla Teixeira Pinheiro and Junior, Howard Lopes Ribeiro},
  title = {The Molecular Impact of Glucosylceramidase Beta 1 (Gba1) in Parkinson’s Disease: a New Genetic State of the Art},
  journal = {Molecular Neurobiology},
  year = {2024},
  volume = {61},
  number = {9},
  pages = {6754--6770},
  doi = {10.1007/s12035-024-04008-8}
}
Kostenlos starten →